At Laurus Labs, we are driven by an ambitious vision to secure market leadership in our core focus areas.

Laurus Labs aspires to become a most-admired pharmaceutical and biotechnology company with a clear focus on four growing areas: APIs, FDFs, synthesis and biotechnology. Our early investments in R&D and manufacturing have enabled us to become a leading manufacturer of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C drugs. We also manufacture APIs for Oncology and other therapeutic areas.

With world-class manufacturing facilities capable of large-scale commercial API production, we are positioned as suppliers of choice for pharmaceutical companies seeking to leverage our technical expertise and cost-effective manufacturing capabilities. Our facilities have received approvals from WHO, USFDA, NIP Hungary, PMDA, KFDA and BfArM. Our state-of-the-art Fixed Dosage Formulations (FDF) manufacturing facility has a capacity of one billion tablets per year, which can be expanded to 5 billion tables per year.

Our Synthesis business leverages our strong process chemistry skills to provide analytical and research services, clinical research supplies, and commercial-scale contract manufacturing services for global pharmaceutical companies. We also develop and manufacture speciality ingredients for use in nutraceuticals, dietary supplements and cosmeceutical products.

Annual Report

We are making great progress on our strategic goals. See our latest annual report.